CDX
(S)-4,4'-(1-METHYL-1,2-ETHANEDIYL)BIS-2,6-PIPERAZINEDIONE
Created: | 2003-07-25 |
Last modified: | 2020-06-05 |
Find Related PDB Entry |
---|
Find related ligands: |
---|
Chemical Details | |
---|---|
Formal Charge | 0 |
Atom Count | 35 |
Chiral Atom Count | 1 |
Bond Count | 36 |
Aromatic Bond Count | 0 |
Chemical Component Summary | |
---|---|
Name | (S)-4,4'-(1-METHYL-1,2-ETHANEDIYL)BIS-2,6-PIPERAZINEDIONE |
Synonyms | ICRF-187 |
Systematic Name (OpenEye OEToolkits) | 4-[(2R)-2-(3,5-dioxopiperazin-1-yl)propyl]piperazine-2,6-dione |
Formula | C11 H16 N4 O4 |
Molecular Weight | 268.269 |
Type | NON-POLYMER |
Chemical Descriptors | |||
---|---|---|---|
Type | Program | Version | Descriptor |
SMILES | ACDLabs | 10.04 | O=C2NC(=O)CN(CC(N1CC(=O)NC(=O)C1)C)C2 |
SMILES | CACTVS | 3.341 | C[CH](CN1CC(=O)NC(=O)C1)N2CC(=O)NC(=O)C2 |
SMILES | OpenEye OEToolkits | 1.5.0 | CC(CN1CC(=O)NC(=O)C1)N2CC(=O)NC(=O)C2 |
Canonical SMILES | CACTVS | 3.341 | C[C@H](CN1CC(=O)NC(=O)C1)N2CC(=O)NC(=O)C2 |
Canonical SMILES | OpenEye OEToolkits | 1.5.0 | C[C@H](CN1CC(=O)NC(=O)C1)N2CC(=O)NC(=O)C2 |
InChI | InChI | 1.03 | InChI=1S/C11H16N4O4/c1-7(15-5-10(18)13-11(19)6-15)2-14-3-8(16)12-9(17)4-14/h7H,2-6H2,1H3,(H,12,16,17)(H,13,18,19)/t7-/m1/s1 |
InChIKey | InChI | 1.03 | BMKDZUISNHGIBY-SSDOTTSWSA-N |
Drug Info: DrugBank
DrugBank data are sourced from datasets licensed under a Creative Common's Attribution-NonCommercial 4.0 International License
DrugBank ID | DB00380 |
---|---|
Name | Dexrazoxane |
Groups |
|
Description | An antimitotic agent with immunosuppressive properties. Dexrazoxane, the (+)-enantiomorph of razoxane, provides cardioprotection against anthracycline toxicity. It appears to inhibit formation of a toxic iron-anthracycline complex. [PubChem] The Food and Drug Administration has designated dexrazoxane as an orphan drug for use in the prevention or reduction in the incidence and severity of anthracycline-induced cardiomyopathy. |
Synonyms |
|
Brand Names |
|
Indication | For reducing the incidence and severity of cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer who have received a cumulative doxorubicin hydrochloride dose of 300 mg/m^2 and would benefit from continued doxorubicin therapy. Also approved for the treatment of extravasation from intravenous anthracyclines. |
Categories |
|
ATC-Code | V03AF02 |
CAS number | 24584-09-6 |
Drug Targets
DrugBank data are sourced from datasets licensed under a Creative Common's Attribution-NonCommercial 4.0 International License
Name | Target Sequence | Pharmacological Action | Actions |
---|---|---|---|
DNA topoisomerase 2-alpha | MEVSPLQPVNENMQVNKIKKNEDAKKRLSVERIYQKKTQLEHILLRPDTY... | unknown | inhibitor |
DNA topoisomerase 2-beta | MAKSGGCGAGAGVGGGNGALTWVTLFDQNNAAKKEESETANKNDSSKKLS... | unknown | inhibitor |
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison
T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS.
Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682
Related Resource References
Resource Name | Reference |
---|---|
PubChem | 298076 |
ChEMBL | CHEMBL1231714 |
CCDC/CSD | ICRFRA10 |